PRODUCTS & SERVICES
Overview
product02
SoVarGen have exclusively developed detection technology of low-level somatic mutations in neurological disorders and created patented animal models with brain somatic mutations that recapitulate human neurological disorders.
These technologies will accelerate development of novel therapeutics targeting brain somatic mutations,
based on drug-repositioning, antisense oligonucleotide, and mRNA therapy.
Currently, we provide genomic test of low-level somatic mutations in epileptic disorders.
Core Technology
 1. Accurate detection of low-level somatic mutations in neurological disorders
20180821_05
2. Patented animal models with brain somatic mutations that recapitulate human neurological disorders
20180821_06
3. Development of novel therapeutics targeting brain somatic mutations, based on drug-repositioning, antisense oligonucleotide, and mRNA therapy
20180821_07
4. Identifying the fundamental causes of human glioblastoma that arises from subventricular zone harboring low-level driver mutations
service03
Service
 We provide genomic test of low-level somatic mutations in epileptic disorders.
Our assays reveal the low-level of brain somatic mutations as genetic causes in up to 40% of childhood intractable epilepsy and match patients to approved targeted therapies, and clinical trials — giving doctors and patients powerful actionable insights for navigating drug-resistant epilepsy.
Revealing the low-level of brain somatic mutations as genetic causes in up to 40% of childhood intractable epilepsy
Matching patients to approved targeted therapies and clinical trials
Giving doctors and patients powerful actionable insights for navigating drug-resistant epilepsy
service02
Service Inquiry
Please contact us if you are interested in our service.
Phone : +82–70–5222-2770
Email : km9555@naver.com